With the extra busy schedules people have these days, fitness tracking apps have helped many people time and track their exercise time, calories burnt and the time taken to do so. These apps also remind us to drink water, not exceed our calorie limits for the day, as well as keep exercising. However, sometimes these devices can have an adverse impact on our health. Instead of making us feel better, they can make us feel anxious or stressed. This generally happens when we become too focused on the numbers and start to worry if they aren't perfect. It's important to understand that while these trackers can be helpful, they shouldn't control our mood or make us feel bad about ourselves.

A recent study published in the Journal of the American Heart Association also found that people with heart problems who used trackers were more worried about their symptoms. With so many people using these devices, it's becoming a common problem. 20% of wearable users felt anxious and always contacted their doctors when they received an irregular rhythm notification. They also found that these devices meant increased monitoring and worrying, higher usage of AFib (atrial fibrillation) specific health care etc. These findings suggest that while wearables can help patients monitor their AFib, they may also lead to increased anxiety and health care use. More research is needed to fully understand the effects of these devices on patients, doctors, and the health care system.

Signs These Apps May Be Getting Too Much For You

We can become too focused on achieving certain goals, like a certain number of steps or a perfect sleep score. This can lead to stress and anxiety when we don't meet those goals, instead of simply using the information to support a healthy lifestyle.

Your Metrics Influence Your Mood

If your happiness or sadness depends on the numbers your fitness tracker shows, it's a sign you might need a break. Getting a low score can make you feel like you've failed, even if you've been making healthy choices. It's normal to feel a little disappointed when you don't reach a goal, but your overall mood shouldn't be affected. If you notice that your mood changes a lot based on your tracker's data, it might be time to step away from it for a while.

You Constantly Try To Interpret Your Numbers

If you find yourself constantly searching online to understand what your tracker's data means, it's a warning sign. Trying to interpret every number can lead to more worry and confusion. You might start to believe you have health problems that don't exist. It's important to remember that these trackers are tools, not medical professionals. Spending too much time trying to decode the data can increase your anxiety instead of helping you.

You Feel Anxious When You Can’t See Your Data

If you feel nervous or anxious when you forget your tracker or it's not working, you might be too dependent on it. You should be able to feel comfortable and relaxed without constant data. If you feel panicky when you can't see your numbers, it's a sign you need to learn to be okay without them. You should be able to trust your body's signals instead of relying only on the tracker.

You’re Ignoring How Your Body Feels

If you rely only on your tracker and ignore what your body is telling you, it's a problem. Your body's signals are important. For example, you might feel well-rested, but if your tracker says your sleep quality is low, you might start to doubt yourself. It's important to listen to your body and not just the numbers. Your body knows when it's tired, hungry, or needs rest. The tracker is a tool to support your health, not replace your body’s signals.

The risk of hantavirus spreading is generally considered low, as repeatedly stated by the World Health Organization (WHO) and other global health agencies, after the recent outbreak on the MV Hondius cruise ship. However, a shocking peer-reviewed study has found that the Andes strain of the rat-borne virus can persist in human semen for up to six years.

More concerning is the possibility that the virus could potentially be transmitted sexually even after a person has recovered, according to the 2023 study published in the journal Viruses.

The research, conducted by Swiss scientists at Spiez Laboratory, suggests that hantavirus may survive in the male reproductive tract like viruses such as Ebola.

What Did The Study Find?

The research team, which included scientists from the University of Bern and the University of Lausanne, investigated a 55-year-old man who had contracted the Andes strain of hantavirus in South America six years earlier.

The researchers discovered that although the virus was no longer detectable in the man’s blood, urine, or respiratory tract, it was still present in his semen 71 months later.

"Viral RNA remained primarily detectable intracellularly in semen samples throughout the complete study period of almost six years," the 2023 study stated,

“Taken together, our results show that the Andes virus has the potential for sexual transmission,” it added. However, so far no confirmed case of such transmission has yet been documented.

Also read: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support

Andes Virus: Male Testes Hidden ‘Reservoirs’?

Hantavirus is not the first virus found to persist in the male reproductive system. According to the study, viruses such as Ebola and Zika are also known to evade the immune system by remaining hidden in the testes for extended periods.

A 2021 Ebola outbreak in Guinea, which resulted in 23 cases and 12 deaths, was later linked to a survivor of the 2014–2016 West Africa epidemic who reportedly transmitted the virus sexually years after recovery.

The testes are considered a biological “safe harbour” for at least 27 infectious diseases, enabling certain pathogens to remain hidden in the body and potentially spread years after a patient has recovered.

Because sperm cells are essential for reproduction, they are shielded from the body’s immune response. However, this immune protection can also create an environment where viruses are able to survive and persist for long periods.

Safe-Sex Guidance For Hantavirus-Infected Individuals

Analysts at Airfinity, a company that tracks global health risks, recommend that male patients should receive “extensive safe-sex guidance beyond the [42-day] quarantine”, the Telegraph reported

The guidance should be “analogous to the World Health Organization’s (WHO) Ebola survivor semen-monitoring protocols,” it added.

The WHO protocols recommend that the semen of male Ebola survivors should be tested every three months and should not be considered virus-free until two consecutive negative test results are obtained.

Until cleared, they should “abstain from all types of sex” or “use condoms consistently and correctly.”

They should also wash themselves “thoroughly” with soap and water after any contact with semen – including after masturbation, according to the guidance.

Hantavirus on MV Hondius

According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.

A Dutch couple is believed to have been first exposed to the virus while visiting a birdwatching site in Argentina.

The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.

While all passengers onboard the cruise have been taken care of by health authorities, the virus' long incubation period is a serious risk factor. Which means that even those asymptomatic can turn infectious 6-8 weeks later.

While GLP-1 weight-loss drugs such as Wegovy and Mounjaro have helped patients lose weight, a major concern has been weight regain once the therapy is stopped. Now, a new study by US scientists suggests that a daily pill may help prevent that rebound weight gain.

According to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian, switching to the once-daily orforglipron pill may not only help maintain weight loss but also preserve cardiometabolic benefits.

Orforglipron is US drugmaker Eli Lilly’s first oral pill for weight loss, marketed as Foundayo. In April, it received approval from the US Food and Drug Administration (FDA).

Weight Loss With Daily Pill Orforglipron

In the Eli Lilly-funded trial, published in the journal Nature Medicine, researchers found that patients in the Phase 3b clinical trial maintained around 75–80 per cent of their weight loss. They also experienced several additional health benefits, including:

• Reduced waist circumference
• Improved blood pressure
• Better blood sugar control
• Lower triglyceride levels
• Improved cholesterol levels

The Clinical Trial

The ATTAIN-MAINTAIN trial enrolled patients who had already achieved substantial weight loss that later plateaued while taking weekly injectable GLP-1 drugs during the SURMOUNT-5 trial.

The study randomized:

• 205 patients taking tirzepatide
• 171 patients taking semaglutide

The results showed that patients switching from tirzepatide to orforglipron maintained an average of 74.7 per cent of their body weight reduction, compared with 49.2 per cent in the placebo group.

Meanwhile, patients who switched from semaglutide to orforglipron maintained 79.3 per cent of their body weight reduction, compared with 37.6 per cent in the placebo arm.

Over the 52-week trial period, participants treated with orforglipron gained:

• An average of 5 kg (11 lbs) in the tirzepatide group
• An average of 1 kg (2.2 lbs) in the semaglutide group

How The Daily Pill Orforglipron Works

Eli Lilly licensed orforglipron, the active ingredient in Foundayo, from a Japanese pharmaceutical company in 2018.

Like injectable GLP-1 drugs, Orforglipron is available in six doses ranging from 0.8 mg to 17.2 mg. Patients typically begin at the lowest dose and gradually increase under medical supervision.

Also read: Donald Trump Will Have Fourth Medical Checkup In May, Says White House

Unlike some oral GLP-1 drugs, people taking orforglipron do not need to restrict food or drink intake after taking the pill. Researchers say the small molecule is absorbed quickly into the bloodstream and reaches target tissues efficiently.

Orforglipron: Side Effects And Safety Concerns

Foundayo is not approved for use in children and carries warnings about potential thyroid tumours, including thyroid cancer.

The drugmaker advises patients to watch for symptoms such as:

• Lump or swelling in the neck
• Hoarseness
• Trouble swallowing
• Shortness of breath

• Nausea
• Constipation
• Diarrhoea
• Vomiting
• Indigestion
• Stomach pain
• Headache
• Swollen belly
• Fatigue
• Belching
• Heartburn
• Gas
• Hair loss.

In a major development for cancer care in India, Swiss pharmaceutical major Roche Pharma has launched Tecentriq SC, the country’s first subcutaneous (under-the-skin) immunotherapy for lung cancer that can be administered in approximately seven minutes.

While conventional intravenous (IV) infusions can take hours, Tecentriq SC can significantly improve the cancer treatment experience by reducing treatment time by nearly 80 per cent.

The seven-minute injectable immunotherapy has the potential to:

• Treat up to five patients in the time taken to treat one patient through intravenous infusion
• Help optimise healthcare resources
• Lower indirect treatment costs
• Minimise the need for patients to travel long distances
• Reduce the amount of time caregivers spend in hospitals

“With Tecentriq SC, we are bringing an innovation that meaningfully reduces treatment time while maintaining the established efficacy and safety profile of Tecentriq. We believe such advances can play an important role in enabling more patient-centric and future-ready cancer care delivery in India,” said Roche Pharma India Chief Medical Officer Dr Sivabalan Sivanesan, in a statement.

What Is Tecentriq SC? What's The Cost In India?

Tecentriq SC is the first and only PD-(L)1 inhibitor globally with both intravenous (IV) and subcutaneous (SC) formulations across multiple cancers.

First approved by the UK MHRA in 2023 and subsequently by the USFDA in 2024, Tecentriq SC is now approved in more than 85 countries, with over 10,000 patients benefitting globally.

In India, Tecentriq SC is currently approved by the DCGI for adjuvant and metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form, making up about 80–85% of all cases.

According to Sivanesan, the drug is priced at about "Rs 3.7 lakh per vial".

Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi

How Does Tecentriq SC Work?

Tecentriq SC combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.

The technology uses recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily increases permeability in the subcutaneous space, enabling rapid dispersion and absorption of the medicine into the bloodstream, the company said.

How Tecentriq SC will Boost Cancer Care In India

The launch of Tecentriq SC also aligns with the broader shift toward decentralised cancer care in India. Shorter administration formats can free up hospital beds, healthcare staff time, and oncology resources at tertiary care centres, while helping shift care delivery to daycare centres and beyond traditional tertiary hospitals.

“India’s growing cancer burden requires us to rethink how cancer care is delivered. Innovations such as subcutaneous immunotherapy have the potential to simplify treatment administration, reduce pressure on hospital beds and support more decentralised models of care beyond large metro hospitals,” said Dr Amit Rauthan, Consultant and HOD of Medical Oncology at Manipal Hospital.

Read More: India Better Prepared For Hantavirus Outbreaks After COVID-19 Experience, Says Dr NK Ganguly | Exclusive

Tecentriq SC: Safety

Global studies have indicated strong patient preference for subcutaneous administration.

According to results from the IMscin002 study presented at the European Lung Cancer Congress (ELCC) 2024:

• Four out of five patients preferred Tecentriq SC over IV administration
• Patients cited less time in clinics, greater comfort, and lower emotional distress as key reasons for preference

Studies have also shown that subcutaneous administration is associated with less discomfort, pain, and irritation compared to IV administration.

In the IMscin001 study presented at ESMO 2023:

• 90 per cent of healthcare professionals agreed the SC formulation was easy to administer
• 75 per cent believed it could save time for healthcare teams.